biostudies-literatureUnknown7(12)Kotwal SS<h4>Importance</h4>Chronic kidney disease (CKD) is a global health priority affecting almost 1 billion people. New therapeutic options and clinical trial innovations such as adaptive platform trials provide an opportunity to efficiently test combination therapies.<h4>Objective</h4>To describe the design and baseline results of the Global Kidney Patient Trials Network (GKPTN) and the design and structure of the global adaptive platform clinical trial Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) to find new therapeutic options and treatments for people with kidney disease.<h4>Design, setting, and participants</h4>The GKPTN is a multicenter registry that started in May 2020 and is ongoing, while CAPTIVATE is a multicenter, multJAMA network opene2449998https://www.ebi.ac.uk/biostudies/studies/S-EPMC11635535biostudies-literatureThe Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.PMC11635535Aucella FYokoo TItano SHour BBrusa MVarley BFukagawa MPatel NBueso GStranks JCasulla JSoler Romeo MJJunwu DPardo EJardine MJWieskopf BMorales Portillo CBusch RMasanori AHe ZLin EHeerspink HJLCournoyer SYu MGuinness Dde Boer IHamilton RYoffe AMcMahon LKotwal SSChow JNappi FChiari ELickey DSantiago JBie LCigarran SKotwal SZulkhernain NSDrabick AGreen AYaozhong KKaveh KHones LKashihara NBai YGray NBai XHong CSimeoni MJha VShanik MMah PMBowman DGregorini MAdeyari CCluigt NTinahones Maduen FJHsu FHChen MRavera MNelson OWada JSoto Gonzalez AArif AReddy AAlvarisqueta APecoits-Filho RKovesdy CMalhotra VWanhong LGarcia DMok CLy MBrusco OAFlavell ASugawara YNangaku MRizzi DYongjun SFranklin JAchiaga FLiu YCoggan SGaite LLiu ZGaite JNumrungroad Vde Boer IHSuzuki YRaymond EMontero MRominger LHou FFMarques MChun ZGorriz JLReid AHammoud JGesualdo LHernandez PGrey VAlicic RXueyan BRamallo PKanade RNaka MTran THGregory VOng SMaurich SMQun LLucas KJArias CShilpakar LZuying XTsukada NZhang HHurndon DToussaint NWheeler DCLewis RJResk JHGKPTN and CAPTIVATE InvestigatorsGuisen LBeusenberg FJin HGomez-Cortez JCha HPBerry LRVelasquez-Mieyer PAShahid NLambers Heerspink HZheng YSwaminathan SCruzado JMPantoja Perez JCisternas PTutt MWeir MAbaterusso CGovindarajulu SDesai ABittar JDombroski EKim DPing FPerkovic VRoger SKim MGohh RShah NAMarioli PAPisani APergola PShabbir NDwivedi SCaili WZhigang MZhou JKirk EDon SYap LXiao YSchneider LVart PCox JRovner SMounsey DQuevedo APeng LKaname SDe Nicola LGoto SWang JBillot LHossain FSun SCambon LLanglois MFHalewood JRui YOla JLayden BCzank CXueai LHo MPollard SLarsheid LGarmack REdris MMonaghan HLong JMcGlothlin AXiaoyong YMarion JArnott CIoasa DAlello JCereto Castro FMayfield RWalker EGold MEsposito Cdi Tanna GLVora SVora PKrishnasamy RAli MTakai MAndreucci MJohnstone MCabrerizo ONarita ILokesh DChua JfalseThe Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.<h4>Importance</h4>Chronic kidney disease (CKD) is a global health priority affecting almost 1 billion people. New therapeutic options and clinical trial innovations such as adaptive platform trials provide an opportunity to efficiently test combination therapies.<h4>Objective</h4>To describe the design and baseline results of the Global Kidney Patient Trials Network (GKPTN) and the design and structure of the global adaptive platform clinical trial Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) to find new therapeutic options and treatments for people with kidney disease.<h4>Design, setting, and participants</h4>The GKPTN is a multicenter registry that started in May 2020 and is ongoing, while CAPTIVATE is a multicenter, mult2024-01-01T00:00:00Z2024 Dec2026-04-17T13:12:07.268Z2025-04-04T02:32:39.364ZS-EPMC116355353966138810.1001/jamanetworkopen.2024.49998